Granule-dependent mechanisms of lysis are defective in CD8 T cells of HIV-infected, antiretroviral therapy-treated individuals

AIDS. 2004 Apr 9;18(6):859-69. doi: 10.1097/00002030-200404090-00003.

Abstract

Background: HIV-specific cytotoxic T-cell (CTL) responses are defective in HIV-infected patients undergoing antiretroviral therapy (ART). This defect has been attributed to the decreased antigenic burden secondary to ART-associated suppression of HIV-replication, and is responsible for the rebounds of viraemia that occur when patients interrupt therapy. CTL are stimulated by type 1 cytokines and can kill targets via granule-dependent (perforin and granzymes) and -independent (tumour necrosis factor-alpha, CD95) mechanisms.

Methods: Granule-dependent and granule-independent mechanisms of CTL killing, as well as type 1 cytokine production by CD4 T cells, were analysed in 57 chronically HIV-infected ART-treated or ART-untreated individuals.

Results: The results can be summarized as follows: the frequency of gp160 (env)-specific interferon-gamma-secreting CD8 T lymphocytes correlates positively with HIV viraemia in ART-treated and -untreated patients; Env-specific perforin- and granzymes-expressing CD8 T lymphocytes, and Env-stimulated perforin and granzymes mRNA, are reduced in ART-treated patients independently of HIV viral load and of type 1 cytokine production; tumour necrosis factor-alpha production is increased in ART-treated individuals; and Env-specific immature CD8+28+27+ cells are only marginally augmented in ART-treated patients, Similar results are observed in cytomegalovirus-specific CD8 T cells and peripheral blood mononuclear cells.

Conclusions: A defect of CTL function that selectively affects the granule-dependent mechanisms of lysis is observed in ART-treated individuals. Because interferon-gamma production is higher in these patients, this could be a defect primarily involving CTL. These data suggest an independence of CD8 T-cell numbers and their lytic ability in HIV-infected, ART-receiving patients. Immunomodulants are needed to successfully treat HIV infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-HIV Agents / therapeutic use
  • Antigens, Viral / immunology
  • Biomarkers / analysis
  • CD28 Antigens / analysis
  • CD4-Positive T-Lymphocytes / immunology
  • CD8-Positive T-Lymphocytes / immunology*
  • Cells, Cultured
  • Chronic Disease
  • Cytomegalovirus / immunology
  • Cytotoxicity, Immunologic
  • Female
  • HIV Infections / drug therapy
  • HIV Infections / immunology*
  • HIV-1*
  • Humans
  • Interferon-gamma / immunology
  • Interleukin-2 / immunology
  • Male
  • Membrane Glycoproteins / analysis
  • Middle Aged
  • Perforin
  • Pore Forming Cytotoxic Proteins
  • Statistics, Nonparametric
  • Tumor Necrosis Factor Receptor Superfamily, Member 7 / analysis
  • Tumor Necrosis Factor-alpha / analysis
  • Viremia / immunology
  • fas Receptor / analysis

Substances

  • Anti-HIV Agents
  • Antigens, Viral
  • Biomarkers
  • CD28 Antigens
  • Interleukin-2
  • Membrane Glycoproteins
  • Pore Forming Cytotoxic Proteins
  • Tumor Necrosis Factor Receptor Superfamily, Member 7
  • Tumor Necrosis Factor-alpha
  • fas Receptor
  • Perforin
  • Interferon-gamma